Safety and lower airway immunogenicity of two candidate Coronavirus Disease (COVID-19) vaccines administered to the respiratory tract

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:1 publications

Grant number: MR/V028499/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $376,989.6
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Imperial College London
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

For a COVID-19 vaccine to have maximum impact, it should not only prevent severe infection but also limit the shedding of virus so that transmission is interrupted and pandemic spread is controlled. Experience with the influenza vaccine FluEnz (which is given as a nasal spray) has shown that intranasal vaccines can be effective for both outcomes. All COVID-19 vaccines currently being trialled are delivered by injection but it is known that directly stimulating immunity at the site of infection (i.e. the nose and lung) induces specialised protective responses that may more quickly and completely control infection. This study will test the two leading UK COVID-19 vaccines to show that they are safe, well-tolerated and capable of stimulating immune responses both in the blood and the lung when administered to the respiratory tract. Using standardised methods, we will directly compare immune responses in the blood, nose and lower airway between these two vaccines as well as with data from ongoing clinical trials of intramuscular vaccination. Thus, we will show the effect of different vaccine technologies as well as delivery method and provide the critical information required to begin further clinical trials to show the efficacy of this needle-free vaccination strategy.

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

Human Challenge Studies with Coronaviruses Old and New.